Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Eva Reijmen"'
TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy
Autor:
Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Yannick De Vlaeminck, Quentin Lecocq, Eva Reijmen, Wout De Mey, Lien De Beck, Thomas Ertveldt, Isabel Pintelon, Jean-Pierre Timmermans, David Escors, Marleen Keyaerts, Karine Breckpot, Cleo Goyvaerts
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. Recent observations indicate a
Externí odkaz:
https://doaj.org/article/8cb0f64de304414d9efd07fa0701e7a3
Autor:
Eva Reijmen, Sven De Mey, Helena Van Damme, Kirsten De Ridder, Thierry Gevaert, Emmy De Blay, Luc Bouwens, Christine Collen, Lore Decoster, Marijke De Couck, Damya Laoui, Jacques De Grève, Mark De Ridder, Yori Gidron, Cleo Goyvaerts
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
The combination of radiotherapy (RT) with immunotherapy represents a promising treatment modality for non-small cell lung cancer (NSCLC) patients. As only a minority of patients shows a persistent response today, a spacious optimization window remain
Externí odkaz:
https://doaj.org/article/f583c94519e047c6b26de319c96a0fda
Autor:
Lieselot Houspie, Philippe Lemey, Els Keyaerts, Eva Reijmen, Valentijn Vergote, Anne Vankeerberghen, Freya Vaeyens, Hans De Beenhouwer, Marc Van Ranst
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60416 (2013)
Molecular surveillance of HRSV in Belgium for 15 consecutive seasons (1996-2011) revealed a shift from a regular 3-yearly cyclic pattern, into a yearly alternating periodicity where HRSV-B is replaced by HRSV-A. Phylogenetic analysis for HRSV-A demon
Externí odkaz:
https://doaj.org/article/75a7de373f7f4a66a4544f2333173d75
Autor:
Kirsten De Ridder, Hanne Locy, Elisa Piccioni, Miren Ibarra Zuazo, Robin Maximilian Awad, Stefaan Verhulst, Mathias Van Bulck, Yannick De Vlaeminck, Quentin Lecocq, Eva Reijmen, Wout De Mey, Lien De Beck, Thomas Ertveldt, Isabel Pintelon, Jean-Pierre Timmermans, David Escors, Marleen Keyaerts, Karine Breckpot, Cleo Goyvaerts
Publikováno v:
Frontiers in immunology
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname
Immune checkpoint blockade (ICB) of the PD-1 pathway revolutionized the survival forecast for advanced non-small cell lung cancer (NSCLC). Yet, the majority of PD-L1+ NSCLC patients are refractory to anti-PD-L1 therapy. Recent observations indicate a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::637189a9817d5664fb7792a00077d19e
https://hdl.handle.net/2454/43383
https://hdl.handle.net/2454/43383
Autor:
Thierry Gevaert, Pieterjan Debie, Hanne Locy, Eva Reijmen, Sandrina Martens, Cleo Goyvaerts, Kirsten De Ridder, Sven De Mey, Luc Bouwens, Jacques De Greve, Wout De Mey, Emmy De Blay, Karine Breckpot, Mark De Ridder
Publikováno v:
International journal of radiation oncology, biology, physics. 111(1)
Purpose The combination of standard-of-care radiation therapy (RT) with immunotherapy is moving to the mainstream of non-small cell lung cancer treatment. Multiple preclinical studies reported on the CD8+ T cell stimulating properties of RT, resultin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b176fb7a8c5d9a2752225288f0e6f928
https://pubmed.ncbi.nlm.nih.gov/33865948
https://pubmed.ncbi.nlm.nih.gov/33865948
Autor:
Gil Awada, Julia Katharina Schwarze, Eva Reijmen, Cleo Goyvaerts, Giuseppe Fasolino, sandrine aspeslagh, Bart Neyns
Publikováno v:
Vrije Universiteit Brussel
Background: Preclinical and clinical data suggest MEK-inhibition (MEKi) to be effective in NRAS-mutant (mt) and NRAS wild-type (wt) melanoma. However, MEKi causes considerable cutaneous treatment-related adverse events (TRAE) which are less present i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::53338b0a6318977da032412bb2b71ab1
https://biblio.vub.ac.be/vubir/interim-safety-and-efficacy-results-of-a-phase-ii-clinical-trial-on-trametinib-and-lowdose-dabrafenib-in-patients-with-advanced-brafv600-wildtype-melanoma(19b30e2a-aed0-4c7c-8591-653b86a4b31c).html
https://biblio.vub.ac.be/vubir/interim-safety-and-efficacy-results-of-a-phase-ii-clinical-trial-on-trametinib-and-lowdose-dabrafenib-in-patients-with-advanced-brafv600-wildtype-melanoma(19b30e2a-aed0-4c7c-8591-653b86a4b31c).html
Publikováno v:
Immunology Letters. 202:38-43
Accumulating evidence points to a beneficial effect ofvagus nerve activity in tumor development. The vagus nerve is proposed to slow tumorigenesis because of its anti-inflammatory properties mediated through ACh and the α7nAChR. Since α7nAChRs are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd6cfe30db76fc61ec1b38a1e64432ee
https://doi.org/10.1016/j.imlet.2018.07.006
https://doi.org/10.1016/j.imlet.2018.07.006
Autor:
Cleo Goyvaerts, Sandrine Aspeslagh, Julia Katharina Schwarze, Giuseppe Fasolino, Bart Neyns, Eva Reijmen, Gil Awada
Publikováno v:
Annals of Oncology. 31:S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bdead6617e2ea93580ec54569f041cce
https://doi.org/10.1016/j.annonc.2020.01.039
https://doi.org/10.1016/j.annonc.2020.01.039
Autor:
Eva Reijmen, Philippe Lemey, A. Vankeerberghen, Marc Van Ranst, Lieselot Houspie, Freya Vaeyens, Valentijn Vergote, Els Keyaerts, Hans De Beenhouwer
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e60416 (2013)
PLoS ONE
PLoS ONE
Molecular surveillance of HRSV in Belgium for 15 consecutive seasons (1996-2011) revealed a shift from a regular 3-yearly cyclic pattern, into a yearly alternating periodicity where HRSV-B is replaced by HRSV-A. Phylogenetic analysis for HRSV-A demon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9f382296807102fd64266e4bccae53
https://biblio.vub.ac.be/vubir/(94bd8088-9ec8-46dd-b576-cae1187a0743).html
https://biblio.vub.ac.be/vubir/(94bd8088-9ec8-46dd-b576-cae1187a0743).html
Autor:
Eva Reijmen, SVEN LUK DE MEY, Helena Van Damme, Thierry Gevaert, Christine Collen, Lore De Coster, Marijke De Couck, Damya Laoui, Karine Breckpot, Jacques De Greve, Mark De Ridder, Yori Gidron, Cleo Goyvaerts
Publikováno v:
Vrije Universiteit Brussel
Radiotherapy (RT) has an established role in the treatment of patients with non-small-cell lung cancer (NSCLC). Unfortunately, tumor irradiation upregulates the expression of various inflammatory cytokines which contribute to radioresistance with sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::5beab8077dd126c7c5e12daf5b08f36f
https://researchportal.vub.be/en/publications/04daa8b0-3004-43cc-bb73-d66694dd549a
https://researchportal.vub.be/en/publications/04daa8b0-3004-43cc-bb73-d66694dd549a